Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

An international registry of patients with plasminogen deficiency (HISTORY).

Shapiro AD, Menegatti M, Palla R, Boscarino M, Roberson C, Lanzi P, Bowen J, Nakar C, Janson IA, Peyvandi F.

Haematologica. 2020 Mar;105(3):554-561. doi: 10.3324/haematol.2019.241158. Epub 2020 Jan 30. Review.

2.

Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time.

Nakar C, Shapiro A.

Transfus Apher Sci. 2019 Oct;58(5):578-589. doi: 10.1016/j.transci.2019.08.008. Epub 2019 Aug 6. Review.

PMID:
31447396
3.

Mathematical model of thrombin generation and bleeding phenotype in Amish carriers of Factor IX:C deficiency vs. controls.

Gupta S, Bravo MC, Heiman M, Nakar C, Brummel-Ziedins K, Miller CH, Shapiro A.

Thromb Res. 2019 Oct;182:43-50. doi: 10.1016/j.thromres.2019.07.020. Epub 2019 Aug 8.

4.

Clinical features of children, adolescents, and adults with coexisting hypermobility syndromes and von Willebrand disease.

Hall SA, Meier ER, Gupta S, Nakar C, Rampersad A, Bakeer N, Hardesty B, Kumar M.

Pediatr Blood Cancer. 2018 Dec;65(12):e27370. doi: 10.1002/pbc.27370. Epub 2018 Aug 7.

PMID:
30084207
5.

Plasminogen replacement therapy for the treatment of children and adults with congenital plasminogen deficiency.

Shapiro AD, Nakar C, Parker JM, Albert GR, Moran JE, Thibaudeau K, Thukral N, Hardesty BM, Laurin P, Sandset PM.

Blood. 2018 Mar 22;131(12):1301-1310. doi: 10.1182/blood-2017-09-806729. Epub 2018 Jan 10.

6.

Safety and efficacy of recombinant factor VIIa by pediatric age cohort: reassessment of compassionate use and trial data supporting US label.

Croteau SE, Nakar C, Neufeld EJ, Shapiro A, Cooper DL.

Pediatr Blood Cancer. 2016 Oct;63(10):1822-8. doi: 10.1002/pbc.26082. Epub 2016 May 27.

PMID:
27232114
7.

Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres.

Nakar C, Manco-Johnson MJ, Lail A, Donfield S, Maahs J, Chong Y, Blades T, Shapiro A.

Haemophilia. 2015 May;21(3):365-73. doi: 10.1111/hae.12608. Epub 2015 Jan 11.

PMID:
25581638
8.

Eukaryotic initiation factor 2α--a downstream effector of mammalian target of rapamycin--modulates DNA repair and cancer response to treatment.

Tuval-Kochen L, Paglin S, Keshet G, Lerenthal Y, Nakar C, Golani T, Toren A, Yahalom J, Pfeffer R, Lawrence Y.

PLoS One. 2013 Oct 25;8(10):e77260. doi: 10.1371/journal.pone.0077260. eCollection 2013.

10.

Rapamycin-sensitive pathway regulates mitochondrial membrane potential, autophagy, and survival in irradiated MCF-7 cells.

Paglin S, Lee NY, Nakar C, Fitzgerald M, Plotkin J, Deuel B, Hackett N, McMahill M, Sphicas E, Lampen N, Yahalom J.

Cancer Res. 2005 Dec 1;65(23):11061-70.

11.

Adenovirus infection in hospitalized immunocompetent children.

Peled N, Nakar C, Huberman H, Scherf E, Samra Z, Finkelstein Y, Hoffer V, Garty BZ.

Clin Pediatr (Phila). 2004 Apr;43(3):223-9.

PMID:
15094946
12.

Mycetoma of the renal pelvis caused by Fusarium species.

Nakar C, Livny G, Levy I, Samra Z, Linder N, Ashkenazi S, Livne P, Sirota L.

Pediatr Infect Dis J. 2001 Dec;20(12):1182-3.

PMID:
11740333
13.

[Antenatal follow-up and the attitude to a newborn of a mother with a positive VDRL test].

Peled N, Nakar C, Ashkenazi S, Merlov P.

Harefuah. 2001 Mar;140(3):266-70. Review. Hebrew. No abstract available.

PMID:
11303358

Supplemental Content

Support Center